Clinical Trials
13 trialsNCT01552434 2026-05-15
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT05826964 2026-01-13
Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer
University of Miami
Phase 2 Active not recruiting
NCT06856200 2025-03-04
A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer
Fudan University
Phase NA Recruiting
NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT02642094 2023-12-05
Aging Mammary Stem Cells and Breast Cancer Prevention
The University of Texas Health Science Center at San Antonio
Phase 2 Terminated
NCT03805399 2022-08-10
FUTURE
Fudan University
Phase 1/2 Unknown
NCT04736589 2021-02-03
Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway
Peking Union Medical College
Phase 3 Not yet recruiting
NCT02145559 2019-04-22
A Pharmacodynamic Study of Sirolimus and Metformin in Patients With Advanced Solid Tumors
University of Chicago
Phase 1 Completed
NCT01797120 2018-05-30
PrE0102
PrECOG, LLC.
Phase 2 Completed
NCT01522820 2016-10-04
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
Roswell Park Cancer Institute
Phase 1 Completed
NCT00411788 2016-09-21
A Phase II Study of Rapamycin and Trastuzumab for Patients With HER-2 Receptor Positive Metastatic Breast Cancer
Yale University
Phase 2 Completed
NCT01155258 2016-06-13
Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
University of Southern California
Phase 1 Completed
NCT00375245 2014-01-17
Rapamycin With Grapefruit Juice for Advanced Malignancies
University of Chicago
Phase 1 Completed